LiveWorld Releases First-Ever AI Brand Reputation Index for Leading Pharmaceutical Brands
Rhea-AI Summary
LiveWorld (OTC: LVWD) has unveiled its first AI Brand Reputation Index, analyzing how artificial intelligence influences perceptions of 50 leading pharmaceutical brands. The study, released on April 15, 2025, employs LiveWorld's proprietary AI framework to evaluate seven weighted reputation factors across major language models including ChatGPT, Perplexity, and Grok.
The index revealed that established brands like Dupixent and Keytruda maintain strong AI reputations due to clinical effectiveness and healthcare professional trust. Notably, Vertex Pharmaceuticals' Trikafta topped the rankings despite advertising, while newer therapies like Leqvio and Rybrevant struggle with AI visibility. The study also highlighted how safety concerns impact AI-driven reputation for products like Remicade and Xeljanz.
The assessment factors included:
- Efficacy
- Safety
- Healthcare professional trust
- Consumer sentiment
- Digital visibility
- Affordability
- Patient loyalty
Positive
- First comprehensive AI Brand Reputation Index for pharmaceutical industry
- Proprietary evaluation framework across major AI language models
- Potential revenue stream from customized brand reputation reports
Negative
- to analysis of only 50 pharmaceutical brands
- Company operates in OTC Markets, indicating lower trading volume/liquidity
Study Highlights Critical Influence of AI-Driven Reputation on Pharma Market Leaders and New Entrants
CAMPBELL, Calif. and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), a pioneer in social-first digital engagement and integrated human-AI solutions, today released its inaugural AI Brand Reputation Index, providing unprecedented insight into how artificial intelligence shapes the perceptions of 50 leading pharmaceutical brands. The comprehensive study identifies key reputation drivers, revealing crucial implications for market leaders and emerging therapies alike.
"As healthcare professionals, patients, and caregivers increasingly rely on AI-driven platforms for information, pharmaceutical brands must understand and actively manage their AI-driven reputations," said Peter Friedman, LiveWorld Chairman and CEO. "This index gives companies actionable insights to strategically enhance their brand positioning and ensure long-term success."
Key Findings from the Report Include:
- Market Leaders Confirmed: Brands with high consumer familiarity and proven efficacy, such as Dupixent, and Keytruda, demonstrated robust AI reputations, driven by clinical effectiveness and healthcare professional trust.
- Advertising Not the Only Driver: Vertex Pharmaceuticals' Trikafta topped the rankings despite limited advertising, showcasing the power of clinical efficacy, healthcare provider endorsement, and authentic patient advocacy in building AI-driven brand perception.
- Challenges for New Therapies: Emerging drugs like Leqvio and Rybrevant struggle with AI visibility, highlighting immediate opportunities for strategic content marketing.
- Safety Perceptions Persist: Products with perceived safety concerns, such as Remicade and Xeljanz, face significant hurdles in AI-driven reputation, underscoring the lasting impact of safety profiles.
- Accessibility Matters: Brands recognized for affordability and patient-friendly access, including Farxiga and Jardiance, enjoyed enhanced AI-driven sentiment.
The study utilizes LiveWorld’s proprietary AI framework assessing seven weighted reputation factors across prominent large language models (LLMs) including ChatGPT (GPT-4), Perplexity, and Grok. These factors encompassed efficacy, safety, healthcare professional trust, consumer sentiment, digital visibility, affordability, and patient loyalty.
Based on the rankings, the study recommends strategic approaches for pharma companies to build up their brand reputation starting with investing in AI-powered brand monitoring and continuous reputation management.
"AI-driven reputation management is no longer optional—it is a strategic imperative," added Friedman. "Brands that proactively engage with their AI presence will significantly outperform their competition."
Helpful Links:
- LiveWorld AI Brand Reputation Index for Pharma Top 50 Brands
- Brands interested in requesting a customized AI brand reputation report for their brand with competitive comparisons may contact us here.
About LiveWorld
LiveWorld is a social-first digital agency and software company that unlocks the full potential of social media to transform customer relationships through integrated compliance, engagement, and insight solutions. We provide brand marketers bold creative rooted in strategy that captivates and resonates, social moderation and engagement that activates interactions, software that enriches customer experiences, and compliance that enables and accelerates digital programs.
With over 28 years of making connections, we leverage our social media DNA to deliver emotion-driven behavior change through digital campaigns with a human touch. LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld.
LiveWorld Contact
PR Contact:
Matthew Hammer
LiveWorld
mhammer@liveworld.com
(737) 212-9739
FAQ
What are the key findings of LiveWorld's (LVWD) AI Brand Reputation Index for pharmaceutical brands?
How does LiveWorld (LVWD) measure AI-driven pharmaceutical brand reputation?
Which pharmaceutical brands performed best in LiveWorld's (LVWD) AI reputation study?
What challenges did LiveWorld's (LVWD) study identify for new pharmaceutical therapies?
How do safety concerns affect pharmaceutical brands' AI reputation according to LiveWorld (LVWD)?
